Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function

Cardiovascular Division, University of Texas Southwestern Medical Center, 5909 Harry Hines Blvd, Room HA9.133, Dallas, TX 75235-9047, USA.
European Heart Journal (Impact Factor: 15.2). 09/2010; 31(18):2262-70. DOI: 10.1093/eurheartj/ehq228
Source: PubMed


To assess the effect of rosiglitazone on cardiovascular performance and cardiac function.
One hundred and fifty type 2 diabetes patients with cardiovascular disease (CVD) or ≥ 1 other CVD risk factor were randomized to receive rosiglitazone vs. placebo for 6 months. The primary outcome was peak oxygen uptake indexed to fat-free mass (VO(2peak)-FFM) during maximum exercise. A subset of 102 subjects underwent cardiac magnetic resonance imaging (cMRI). On hundred and eight subjects completed the study, including 75 completing the cMRI substudy. No significant differences were observed in mean VO(2peak)-FFM between rosiglitazone and placebo (26.1 ± 7.0 vs. 27.6 ± 6.6 mL/kg-FFM/min; P = 0.26). Compared with placebo, the rosiglitazone group had lower hematocrit (38 vs. 41%; P < 0.001) and more peripheral oedema (53.7 vs. 33.3%; P = 0.03). In the cMRI substudy, compared with placebo, the rosiglitazone group had larger end-diastolic volume (128.1 vs. 112.0 mL; P = 0.01) and stroke volume (83.7 vs. 72.9 mL; P = 0.01), and a trend toward increased peak ventricular filling rate (79.4 vs. 60.5; P = 0.07).
Rosiglitazone increased peripheral oedema but had no pernicious effects on cardiovascular performance or cardiac function, with modest improvement in selected cMRI measures. Changes in indirect markers of plasma volume suggest expansion with rosiglitazone. Trial registration: identifier: NCT00424762.

Download full-text


Available from: Raphael See,
12 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the past 3 years, several studies have reignited the controversy regarding the cardiovascular risk associated with the use of rosiglitazone. Until a prospective, well-controlled, randomized clinical trial is performed to adjudicate the issue definitively, physicians should be free to exercise clinical judgment, and weigh the comparative risks and benefits of agents such as rosiglitazone on a case-by-case basis.
    Nature Reviews Cardiology 12/2010; 7(12):670-2. DOI:10.1038/nrcardio.2010.160 · 9.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fluid retention increases intravascular volume and pressure. The calculations in this paper demonstrate that fluid retention increases the likelihood that blood will flow in a turbulent manner, in part due to an increase in stroke volume, regardless of whether or not blood pressure is increased. Increased turbulence will promote endothelial dysfunction, thereby contributing to the development of atherosclerotic cardiovascular disease. Accordingly, fluid retention is predictably detrimental to the cardiovascular system. The reason that some medications, such as cyclo-oxygenase-2 inhibitors, nonselective nonsteroidal anti-inflammatory drugs, estrogens, progestins, and rosiglitazone, are associated with an increased risk of myocardial infarcts and strokes may be that they cause fluid retention. Increased stroke volume and/or edema formation may indicate that a medication increases the risk of adverse cardiovascular events. For drugs that increase the risk of adverse cardiovascular events, it may be possible to reduce or neutralize the increased risk by simultaneously administering a diuretic.
    Clinical hemorheology and microcirculation 01/2011; 47(2):79-86. DOI:10.3233/CH-2010-1369 · 2.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thiazolidinediones cause peripheral oedema, the aetiology of which remains poorly understood. In a sub-study of a 6-month trial comparing rosiglitazone (Rsg) versus placebo, we compared those with versus without oedema among the 74 subjects treated with Rsg with respect to peak oxygen consumption indexed to fat-free mass (VO(2peak-FFM) ), cardiac MRI and markers of plasma volume expansion. Almost half (49%) of the Rsg-treated patients developed oedema. Baseline VO(2peak-FFM) was not different between those with versus without oedema (25.8 versus 28.2 ml/kg/min; p = 0.22) and declined 5% in the oedema group (Δ -1.3 ml/min/kg; p = 0.005) with no change in those without oedema. Stroke volume increased in both groups (Δ 8.7 and 8.8 ml; p < 0.001 for each); end-diastolic volume increased only in those with oedema (+13.1 ml; p = 0.001). No other cardiac function changes were observed. In both groups, weight increased (3.6 and 2.2 kg) and haematocrit decreased (-3.2% and -2.1%; p < 0.001 for each). In those with oedema, albumin decreased (-0.2 g/dl) and brain natriuretic peptide increased (11.9 pg/ml; p < 0.03 for each). Oedema was associated with a small decline in VO(2peak FFM), no adverse effects on cardiac function, and changes in selected measures suggesting that volume expansion underpins Rsg oedema.
    Diabetes & Vascular Disease Research 04/2011; 8(2):101-8. DOI:10.1177/1479164111403334 · 2.83 Impact Factor
Show more